... a tentative settlement to conclude the one remaining antitrust lawsuit involving one of the Company's combined hormonal contraceptives, Ovcon 35. ...
The decline in OVCON revenue was primarily due to the introduction of generic versions of OVCON 35 beginning in late October 2006, which led to an 88.3% ...
... Aveng increased R2,01, or 3,09%, to R67, while Raubex Group grew two rand, or 5,56%, to R38 and Wilson Bayly Holmes-Ovcon pocketed R5,85, or 4,64%, ...
FDA in November 2003 approved the chewable version of Northern Ireland-based Galen Holdings' oral contraceptive Ovcon 35. ...
Murray and Roberts (MUR) slumped 51c to R88.99, but Wilson Bayly Holmes-Ovcon (WBO) advanced 3.41% to R115.30. SABMiller (SAB) lost 2.19% to R191.70, ...
... two antitrust lawsuits involving one of the Company's combined hormonal contraceptives, Ovcon 35, brought by certain direct purchaser plaintiffs. ...
The agreement with Barr granted the company an exclusive license to Barr’s abbreviated new drug application referencing Warner Chilcott’s Ovcon 35. ...
... two antitrust lawsuits involving one of the Company's combined hormonal contraceptives, Ovcon 35, brought by certain direct purchaser plaintiffs. ...
The lawsuits involve the company's hormonal contraceptive Ovcon 35. Shares of Warner Chilcott (nasdaq: WCRX - news - people ) closed at $18.39 Thursday.
... two antitrust lawsuits involving one of the Company's combined hormonal contraceptives, Ovcon 35, brought by certain direct purchaser plaintiffs. ...